Direct
NAV (24-Jul-24)
Returns (Since Inception)
Fund Size
₹2,479 Cr
Expense Ratio
0.64%
ISIN
INF740KA1LG1
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
30 Nov 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+46.19%
+45.90% (Cat Avg.)
3 Years
+18.65%
+14.66% (Cat Avg.)
5 Years
+31.51%
+26.30% (Cat Avg.)
Since Inception
+27.39%
— (Cat Avg.)
Equity | ₹2,431.07 Cr | 98.06% |
Others | ₹48.19 Cr | 1.94% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹309.89 Cr | 12.50% |
Suven Pharmaceuticals Ltd | Equity | ₹232.64 Cr | 9.38% |
Cipla Ltd | Equity | ₹205.25 Cr | 8.28% |
Ipca Laboratories Ltd | Equity | ₹181.2 Cr | 7.31% |
Lupin Ltd | Equity | ₹177.14 Cr | 7.14% |
Globus Medical Inc Class A | Equity | ₹133.06 Cr | 5.37% |
Alembic Pharmaceuticals Ltd | Equity | ₹124.79 Cr | 5.03% |
Apollo Hospitals Enterprise Ltd | Equity | ₹115.18 Cr | 4.65% |
Zydus Lifesciences Ltd | Equity | ₹111.41 Cr | 4.49% |
Concord Biotech Ltd | Equity | ₹96.75 Cr | 3.90% |
Procter & Gamble Health Ltd | Equity | ₹80.15 Cr | 3.23% |
Vijaya Diagnostic Centre Ltd | Equity | ₹76.32 Cr | 3.08% |
Alkem Laboratories Ltd | Equity | ₹72.73 Cr | 2.93% |
Kovai Medical Center & Hospital Ltd | Equity | ₹70.82 Cr | 2.86% |
Intuitive Surgical Inc | Equity | ₹69.67 Cr | 2.81% |
Indoco Remedies Ltd | Equity | ₹67.94 Cr | 2.74% |
Illumina Inc | Equity | ₹45.64 Cr | 1.84% |
ICICI Lombard General Insurance Co Ltd | Equity | ₹43.2 Cr | 1.74% |
Unichem Laboratories Ltd | Equity | ₹39.13 Cr | 1.58% |
Aarti Drugs Ltd | Equity | ₹37.22 Cr | 1.50% |
Narayana Hrudayalaya Ltd | Equity | ₹35.88 Cr | 1.45% |
Net Receivables/Payables | Cash | ₹28.44 Cr | 1.15% |
Abbott Laboratories | Equity | ₹27.4 Cr | 1.11% |
Global X Genomics & Biotechnology ETF | Mutual Fund - ETF | ₹21.35 Cr | 0.86% |
Treps / Reverse Repo Investment | Cash - Repurchase Agreement | ₹19.73 Cr | 0.80% |
Gland Pharma Ltd | Equity | ₹18.09 Cr | 0.73% |
Medplus Health Services Ltd | Equity | ₹13.11 Cr | 0.53% |
Jupiter Life Line Hospitals Ltd | Equity | ₹12.52 Cr | 0.51% |
Pfizer Ltd | Equity | ₹11.48 Cr | 0.46% |
GRAIL Inc | Equity | ₹1.12 Cr | 0.05% |
Large Cap Stocks
31.15%
Mid Cap Stocks
26.23%
Small Cap Stocks
40.63%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,366.54 Cr | 95.45% |
Financial Services | ₹43.2 Cr | 1.74% |
Standard Deviation
This fund
14.78%
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
0.77
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since November 2018
Since December 2020
ISIN | INF740KA1LG1 | Expense Ratio | 0.64% | Exit Load | No Charges | Fund Size | ₹2,479 Cr | Age | 30 Nov 2018 | Lumpsum Minimum | ₹100 | Fund Status | Open Ended Investment Company | Benchmark | BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹1,58,660 Cr
Address
West Wing, 11th Floor, Mumbai, 400021
Your principal amount will be at Very High Risk